- Longo DL, Fauci AS, Kasper D, Hauser S, Jameson J, Loscalzo J. Harrison's Principles of Internal Medicine. 18th ed. New York, NY: McGraw-Hill; 2012.
- Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med. 1965;58(1):9–20.
- Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67(3):103–108. doi:10.15585/mmwr.mm6703a5.
- Lecrenier N, Beukelaers P, Colindres R, et al. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention. Expert Rev Vacc. 2018;17(7):619–634. doi:10.1080/14760584.2018.1495565.
- Heineman TC, Cunningham A, Levin M. Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine. Curr Opin Immunol. 2019;59:42–48. doi:10.1016/j.coi.2019.02.009.
- James SF, Chahine EB, Sucher AJ, Hanna C. Shingrix: the new adjuvanted recombinant herpes zoster vaccine. Ann Pharmacother. 2018;52(7):673–680. doi:10.1177/1060028018758431.
- Bastidas A, Serna J, Idrissi ME, et al; ZOE-HSCT Study Group Collaborators. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA. 2019;322(2):123–133. doi:10.1001/jama.2019.9053.
- Dagnew AF, Ilhan O, Lee W, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019;19(9):988–1000. doi:10.1016/S1473-3099(19)30163-X.
- Ortiz-Brizuela E, Leal-Vega F, Cuellar-Rodriguez J, Bobadilla-Del-Valle M, Ponce-de-Leon A. Vaccine-derived varicella zoster infection in a kidney transplant recipient after zoster vaccine live administration. Vaccine. 2019;37(27):3576–3579. doi:10.1016/j.vaccine.2019.05.017.
- Schwarz TF, Aggarwal N, Moeckesch B, et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older. J Infect Dis. 2017;216(11):1352–1361. doi:10.1093/infdis/jix481.
- Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–1032. doi:10.1056/NEJMoa1603800.
- Thompson H, Nichols L, Gonzalez Santiago T. Bullous fixed drug eruption following administration of the recombinant adjuvant Shingrix vaccine. BMJ Case Rep. 2021;14(8):e241293. doi:10.1136/bcr-2020-241293.
- Bell H, Kamal N, Wong U. Blistering autoimmune skin reaction following SHINGRIX vaccination in an ulcerative colitis patient: case report and literature review. Vaccine. 2020;38(47):7455–7457. doi:10.1016/j.vaccine.2020.09.073.
- Kohn D, Wetzig T. Zostererkrankung nach Shingrix-Impfung [Zoster disease after Shingrix vaccination]. Hautarzt. 2021;72(8):729–732. doi:10.1007/s00105-020-04738-5.
- Anderson TC, Masters NB, Guo A, et al. Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years: recommendations of the Advisory Committee on Immunization Practices—United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(3):80–84. doi:10.15585/mmwr.mm7103a2.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 35, 2022 - Issue 5
Case Studies
Dermatomal rash after Shingrix vaccination: cause or coincidence?
Nitish Mittala School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas
https://orcid.org/0000-0002-7168-2550
, BShttps://orcid.org/0000-0002-7168-2550, , MD & , MD